Table 2

Summary statistics for our study and published reports

Antibodies used
ReferenceNCancers studiedMLH1MLH2% Sensitivity (95% CL)Specificity (%)% PPV% NPV
CL, confidence limit; MSI, microsatellite instability; MSS, microsatellite stable.
Thibodeau et al (1996)8265 cancers with germline MLH1 mutationsPharMingenOncogene72 (55 to 89)10010050 (39 to 78)
3 cancers with germline mutationsG168-728FE11
11 MSI cancers
7 MSS cancers
Marcus et al (1999)9725 cancers with germline MHL1 mutationsPharMingenOncogene97 (93 to 100)10010097 (93 to 100)
11 cancers germline MHS2 mutationsG168-728FE11
22 MSI cancers
34 MSS cancers
Dieumegard et al (2000)10315 germline MLH1 mutations carriersOncogeneOncogene77 (61 to 92)10010085 (72 to 98)
3 germline MSH2 mutations carriersClone Ab-1Clone FE11
6 MSI cancers
17 MSS cancers
Our present study464 germline MLH1 carriersOncogeneOncogene96 (90 to 100)10010096 (90 to 100)
19 MSI cancersClone FE11
23 MSS cancers